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Abstract
Background and Aim: Adalimumab [ADA] was approved for the treatment of ulcerative colitis [UC] 
refractory to conventional therapy in 2012 in Europe. Due to the observed discrepancies between 
clinical trials and practice, data on the outcome of ADA therapy are really needed from the real life. 
The aim of this study was to estimate the short- and long-term efficacy and safety of ADA in UC 
patients from each Hungarian biological centre.
Patients and Methods: This prospective study consisted of UC patients treated with ADA in 10 
Hungarian inflammatory bowel disease centres. The primary endpoints of the study were rates 
of continuous clinical response, remission, non-response and loss of response at Weeks 12, 30, 
and 52.The secondary endpoints included mucosal healing at Week 52 and the comparison of the 
efficacy of ADA between biological naive and infliximab [IFX]-treated groups. Colonoscopy was 
performed before starting the therapy and at Week 52.
Results: In all, 73 active UC patients were enrolled in the study: 67.1% of the patients received 
previous IFX therapy; 75.3% of the patients showed short-term clinical response at Week 12. 
The probability of maintaining ADA was 48.6% at Week 52 with a continuous clinical response 
in 92% of these remaining patients. Mucosal healing was achieved in 48.1% of the patients 
at Week 52. Escalation of ADA was performed in 17.6%, and minor side effects developed in 
4% of the patients; 5.4% of the patients underwent colectomy during the 1-year treatment 
period.
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Conclusion: UC is a progressive disease that may need early aggressive therapy to prevent 
structural and functional complications. The results of our study demonstrated the favourable 
efficacy of short- and long-term ADA treatment for patients with UC.
Key Words:  Ulcerative colitis; adalimumab; continuous clinical response; mucosal healing
1. Introduction
Ulcerative colitis [UC] is a chronic autoimmune condition characterised 
by various disease courses. It seems that almost half of the patients have 
severe, chronic continuous or chronic intermittent disease type.1 These 
patients are frequently faced with severe relapses which require corticos-
teroid therapy with the possibility of hospitalisation or even colectomy. 
The risk of serious complications can be decreased by using immunosup-
pressive and/or biological agents. Infliximab [IFX], a chimeric monoclo-
nal anti-tumour necrosis factor [anti-TNF] antibody proved its efficacy 
for inducing and maintaining remission in moderate-to-severe UC in the 
ACT study2 and was approved by the Europe, Middle East and Africa 
[EMEA], among others, for the treatment of UC in 1997. Despite the 
favourable results came from trials or clinical observations, consider-
able unmet needs remain in addition to the chimeric nature and route of 
administration related to IFX. Recently—after the significantly positive 
results observed in two clinical studies—the fully human IgG1 anti-TNF 
antibody, the subcutaneously administered adalimumab [ADA], also 
gained approval by the EMEA in 2012,3,4 5 years later than in Crohn’s 
disease did. Because usually there is a discrepancy between clinical trials 
and practice,5 and there is an expert opinion that the regular dose of ADA 
might have been underpowered in UC,6 there is a great need of data from 
real life. Although more than 2 years have gone by since the licensing, 
few real clinical experiences have been published to date7,8,9,10,11,12,13 and 
some of them are retrospective analysis with relatively low numbers of 
patients. Therefore our goal was to prospectively collect data of every 
ADA-treated UC patient from each Hungarian biological centre after 
the approval of drug for treatment of moderate to severe UC, and to esti-
mate the short- and long-term efficacy and safety of this biological drug.
2. Patients and Methods
This prospective study consisted of UC patients treated with ADA 
in 10 Hungarian tertiary gastroenterology and inflammatory bowel 
disease [IBD] centres between 2013 and 2014. Eligible patients 
included males and females with an established diagnosis of UC and 
with clinically and endoscopically active disease defined by Mayo 
Scoring System. A  shared common database was used to collect 
demographic and clinical data. Medical records as to gender, dis-
ease extension, disease duration, ADA induction and maintenance 
regimen, the need for dose escalation or discontinuation of ADA, 
concomitant medications, previous IFX therapy, response to ADA 
therapy at Weeks 12, 30, and 52, C-reactive protein [CRP] levels, 
side effects, the need for colectomy, and the assessment of mucosal 
healing at Week 52 were collected.
The primary endpoints of the study were rates of clinical remis-
sion, response and non-response at Week 12, rates of continuous clin-
ical response, remission and loss of efficacy at Weeks 30 and 52, and 
proportion of patients remaining on ADA therapy at the end of the 
first year. The secondary endpoints included mucosal healing at Week 
52 and comparison of the efficacy of ADA between biological naive 
and IFX-treated groups. Patients were clinically assessed at Weeks 
0, 12, 30, and 52. Colonoscopy was performed before starting the 
therapy and at Week 52. Only patients with Mayo endoscopic sub-
score of at least 2 were enrolled in the study. Clinical remission was 
defined as complete steroid withdrawal, and as a partial Mayo sub-
score [pMayo score] ≤ 2, with no individual subscores >1; response 
to ADA was specified as decreasing in pMayo by 3 or more points. 
Continuous clinical response was defined as a maintained response 
through Week 52 without intermediate relapse. Mucosal healing was 
defined as Mayo endoscopic subscore [eMayo]of 0 and 1.
Deep remission assessed at Week 52 was defined as clinical 
and endoscopic remission. Categorical data were analysed using 
Pearson’s chi-square test or Fisher’s exact test. The effects of drug 
therapy on the CRP and pMayo were examined with repeated 
measures analysis of variance [ANOVA]. A  statistical per-protocol 
analysis was performed to evaluate primary efficacy. Paired samples 
t-testing was used to evaluate the change in eMayo scores. Statistical 
tests were performed using R statistical software [R version 3.1.2]; 
values of p < 0.05 were considered significant.
3. Results
A total of 73 active UC patients with a mean age at diagnosis of 
30.8  years [range: 5–56  years] were prospectively enrolled in this 
multicentre study; 49 patients [67.1%] had received previous IFX 
therapy. The main reasons for IFX discontinuation and switch to 
ADA were: primary non-response in 10 patients [20.4%]; loss of 
response in 18 patients [36.7%]; acute or delayed infusion reaction 
in 18 patients [36.7%]; and other reasons in 3 patients [6.1%]. Of 
the total, 32.9% were on steroids and 52% on immunosuppressants 
at inclusion. The patients’ demographic and clinical data are sum-
marised in Table 1; 95.9% of patients received an induction dose of 
ADA 160 mg at Week 0 and then 80 mg at Week 2, and 3 did not.
Table 1. Demographic and clinical features of the patients enrolled 
in the study.
Gender [male/female] Number of patients [n=73]
40/33
Mean age at the diagnosis [years] 30.8 [5–56]
Mean disease duration of adali-
mumab therapy [years]
10.8 [1–43]
Disease extent
-Proctitis 13
-Left-sided colitis 14
-Extent colitis 46
Previous infliximab 49
Steroid-refractory UC 15
Steroid dependency 54
Concomitant medications
-5-ASA 59
-Corticosteroid 24
-Azathioprine 38
Dose intensification of adalimumab 13
Side effect 3
Colectomy 5
Mucosal healing at Week 52 [%] 48.1
UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid.
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At baseline, mean pMayo score was 7.1, mean Mayo endoscopic 
subscore was 2.7 and mean CRP was 15.7 mg/l. At Week 12, 24.7% 
of the patients did not respond to induction therapy. Clinical response 
and remission were achieved in 49.3% and 26% of the patients, 
respectively. At Week 30, loss of response occurred in further 9.1% 
of the patients. Clinical response and remission were achieved in 
34.1% and 56.8% of the remaining patients, respectively. At Week 
52, loss of response developed in 8.3% of the remaining patients, 
whereas clinical response and remission were achieved in 33.3% 
and 58.3% of the patients, respectively. Of the patients originally 
enrolled , 45.2% showed continuous clinical response at Week 52.. 
Rates of non-responders, responders, and patients with remission at 
Weeks 12, 30, and 52 are summarised in Figure 1. Figure 2 includes 
a Kaplan-Meier curve showing the relapse-free survival of patients 
treated with ADA; pMayo and CRP levels decreased significantly at 
Week 12 [p < 0.001, p < 0.001], Week 30 [p < 0.001, p < 0.001], and 
Week 52 [p < 0.001, p = 0.03] compared with the beginning of ADA 
therapy. However, no further significant improvement was statisti-
cally seen in the clinical activity and CRP levels at Week 30 or Week 
52 compared with Week 12. Changes in pMayo scores and CRP 
levels during the treatment period are presented in Figure 3. Dose 
escalation with the increase of ADA dose to weekly administration 
was needed in 13 [17.8%] patients. ADA was stopped in 20 patients 
before the end of the first year [47.5% primary non-response, 17.5% 
loss of response, 7.5% intolerance, 35% non-compliance, and oth-
ers]. Minor side effects developed in three patients [skin rash in two 
patients, fatigue and myalgia in one patient] during the whole ther-
apy. No serious infection, tuberculosis [TB] or malignancy occurred 
during the treatment period. Colectomy was required in five [5.4%] 
patients during the 1-year treatment period.
Previous IFX therapy did not influence disease outcome, the need 
of dose intensification, or the frequencies of side effects in patients 
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Figure 1. Rates of non-responders, responders and patients with remission at Weeks 12, 30, and 52.
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Figure 2. Kaplan-Meier curve showing a relapse-free survival of patients treated with ADA [adalimumab].
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receiving ADA and 48.1% of the patients achieved mucosal healing 
at Week 52. Mean value of endoscopic Mayo subscore decreased 
significantly at Week 52 [p < 0.001]. Deep remission was shown in 
55.6% of the patients at Week 52.
4. Discussion
This prospective multicentre study describes the efficacy and safety 
of ADA therapy in patients with active UC refractory to conventional 
medications, from real-life clinical practice with the collaboration 
of all IBD centres in Hungary. Two-thirds of the enrolled patients 
received IFX previously—the main indication of ADA therapy in 
these patients was loss of response—and 75.3% of the patients 
showed short-term clinical response at Week 12. The probability of 
maintaining ADA was 48.6% at Week 52, with a continuous clinical 
response in 92% of these remaining patients. Mucosal healing was 
shown to have been achieved in almost 50% of the patients at Week 
52. Escalation of ADA was performed in 17.8%, and minor side 
effects developed in 4.1% of the patients. Of all the patients, 5.4% 
underwent colectomy during the 1-year treatment period.
The subcutaneously administered fully human anti TNF-α ADA 
was approved for the treatment of active, refractory UC in 2012 
in Europe. ULTRA 1 and 2 were the first randomised controlled 
clinical trials that confirmed the efficacy of ADA in UC after the 
previous beneficial results in Crohn’s disease. In the ULTRA 1 trial, 
16.9% of patients achieved steroid-free remission at 8 weeks with 
ADA ,160 mg/80 mg/40 mg every other week, compared with 9% 
of patients on placebo. In the ULTRA 2 trial, of 494 patients with 
chronic active UC treated with induction and maintenance regi-
mens of ADA, clinical response was seen at Week 52 in 30.2% and 
18.3% of patients in the treatment and placebo arms, respectively.3,4 
However, response rates for anti-TNF agents in real-life clinical 
practice are less well defined. Despite the time elapsed from the 
authorisation of ADA therapy in UC, only limited data have become 
available from everyday practice that might resolve the apparent dis-
crepancies between clinical trials and practice.
A 52-week, randomised, placebo-controlled, double-blind 
Japanese study evaluated the efficacy of ADA for induction and 
maintenance treatment in UC patients refractory to corticosteroid 
and/or immunomodulator therapy.9 At Week 8, ADA induction ther-
apy at 160/80 mg was superior to placebo in achievement of early 
response and mucosal healing compared with an induction dose of 
80/40 mg. At Week 52, ADA 40 mg had achieved significantly higher 
rates of remission, response, and mucosal healing compared with 
placebo. In this study, clinical remission [23%] and response [31%] 
rates after 52 weeks of ADA therapy were similar to those observed 
in large, pivotal clinical trials.
Gies et al. examined the response rates and long-term outcomes of 
IFX and ADA treatment among 53 outpatients with UC during a median 
follow-up time of 1.3 years.10 According to their results, ADA proved 
to be as effective as IFX in real-life out patient treatment. Induction 
response rates also proved to be higher for ADA [80%] compared with 
the ULTRA trials.3,4 This was probably due to the physician’s global 
response assessment used for the evaluation of clinical response rather 
than the use of a defined full Mayo score and because response was 
assessed at Week 14 of induction therapy rather than at Week 8, as used 
in the clinical trials. In a study by Tursi et al.11 clinical remission was 
obtained in 73.3% and 100% of UC outpatients on ADA therapy previ-
ously treated with IFX at Weeks 24 and 54, respectively. Our results also 
confirm a moderately higher efficacy of ADA both short termand long 
term than was seen in the large clinical trials. More than one-third of our 
patients showed clinical response at Week 12 and 45% at Week 52 and 
more than 90% of the patients who did not lose response atWweek 52 
showed continuous clinical response at the end of the 1-year treatment 
period. Notably, no further significant improvement was statistically seen 
in the clinical activity at Week 30 or Week 52 compared with Week 12, 
which may be related to a rapid response to the ADA induction doses. 
Armuzzi et al. reported data on the effectiveness of ADA in UC patients 
treated in 22 Italian centres. Clinical remission rates proved to be 28.4%, 
36.4%, and 43.2% at 12, 24 and 54 weeks, respectively ,showing lower 
rates than in our study. However, 49.1% of the patients who underwent 
colonoscopy after a median time of 11  months achieved endoscopic 
remission and among them 26.3% achieved complete mucosal healing, 
and this was nearly similar to our results.14
Although the development of antibodies to the drug can not be 
totally avoided, ADA is thought to be less immunogenic than IFX 
because of its fully human structure. Therefore, studies examining the 
efficacy of ADA in patients who previously responded to IFX and then 
lost response or became intolerant have high importance. The study 
of Taxonera et al.12 was one of the first that evaluated the outcomes 
of ADA in UC patients previously treated with IFX. Clinical response 
and remission at Week 12 was achieved in 60% and 27% of the 
patients who were treated with ADA after failure of IFX, respectively. 
All patients who achieved clinical response at Week 12 were colec-
tomy free in the long term. In our cohort, more than two-thirds of 
the patients were switched from IFX to ADA mainly because loss of 
response. Loss of response or intolerance to IFX is highly a significant 
problem in patients with UC. Our results, in accordance with those of 
Taxonera et al., confirm that patients with UC who lost response to or 
became intolerant of IFX may benefit from switching to ADA. In our 
cohort, 42% of the patients treated with previous IFX showed continu-
ous clinical response after switching to ADA. It is also important to 
mention that previous IFX therapy did not influence disease activity, 
the need of dose intensification, or the frequencies of side effects in our 
patients who were switched to ADA. ADA dose escalation was needed 
in 23% and colectomy was required in 20% of the patients in the 
study of Taxonera et al.12 None of these patients undergoing colectomy 
showed clinical response to ADA at Week 12 and half of these patients 
needed colectomy within the first 12 weeks. In the study of Armuzzi 
et al,14 ADA dose escalation was necessary in 35.2% of the patients 
and 25% underwent colectomy because of primary failure or second-
ary loss of response to ADA therapy after a median of 5.5 months Both 
studies revealed higher rates of dose escalation and colectomy than in 
our patient cohort, which may be explained by the more common use 
of concomitant immunosuppression at inclusion in our patients.
0
week 0 week 12 week 30 week 52
2
4
6
8
10
12
14
16
18
16.3
9.0
7.2
3.5 2.9
2.8
7.8
7.1
pMayo (points)
CRP (mg/L)
Figure 3. Changes in partial Mayo [pMayo] subscores and C-reactive protein 
[CRP] levels at Weeks 12, 30, and 52.
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Similarly to our results, rates of clinical response, remission, and 
mucosal healing in ADA-treated patients who had lost response or 
developed intolerance to IFX were similar in IFX-naive and previ-
ously exposed patients in the study of Afif et al.8. Not only the fact 
of previous IFX therapy, but also the response to that, may be impor-
tant to predict the outcome of ADA therapy. The study of Garcia-
Bosch et al. revealed that response to prior treatment with IFX was 
the only predictive factor of response to ADA at Week 12.13
The main limitation of our study is that immunogenicity, ie occur-
rence of anti-ADA antibodies, was not evaluated. However, in clinical 
practice it is uncommon to determine serum trough levels and anti-
body formations at every visit, mainly due to financial reasons. The 
majority of the clinical studies from real life did not investigate the 
efficacy of ADA on mucosal inflammation, although endoscopy is the 
most objective measure of efficacy. Mucosal healing was achieved in 
43% of the patients in the ULTRA 2 trial, 49% in the study of Armuzzi 
et al., and 48% of our cohort—showing highly identical results.
UC is still a progressive disease that may need an early aggressive 
therapy to prevent the structural and functional complications. Anti-
TNF therapies are useful to achieve these goals. The results of our 
study and those detailed above demonstrated the favourable efficacy 
of short- and long-term ADA treatment for patients with UC. Our 
results revealed that patients responded well to long-term therapy, 
with stable remission and mucosal healing rates.
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